SOMERSET, NJ — Solco Healthcare announces its FDA approval for Amphetamine Sulfate tablets, 5mg and
10mg, which is an AA-rated equivalent to Evekeo® by Arbor Pharmaceuticals.

“This approval represents Solco’s first CII product within the ADHD therapeutic treatment. Amphetamine
sulfate tablets will be manufactured in our Prinston Laboratories facility located in Charlotte, NC. We are
launching this product at an unprecedented time surrounding the COVID-19 pandemic, while taking extra
precautions at our manufacturing facility to ensure the protection of our personnel and our operations.”,
said Hai Wang, President of Solco Healthcare. Amphetamine sulfate tablets are indicated for (1) Narcolepsy
and (2) Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which
typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in
children with behavioral syndrome. According to IQVIA, total market sales for Amphetamine Sulfate tablets
for the last twelve months ending February 2020 were $36.2 million.

Solco Healthcare will market Amphetamine Sulfate tablets, 5mg and 10mg in 100 count bottles. Solco anticipates this product will be available for distribution in mid-April 2020. Please contact your Solco Healthcare National Accounts Manager or customer service at (855) 581-9688 for more information.